PRGO vs. CORT, SUPN, PCRX, JAZZ, INSM, ALKS, BHVN, RARE, CBAY, and OGN
Should you be buying Perrigo stock or one of its competitors? The main competitors of Perrigo include Corcept Therapeutics (CORT), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Jazz Pharmaceuticals (JAZZ), Insmed (INSM), Alkermes (ALKS), Biohaven (BHVN), Ultragenyx Pharmaceutical (RARE), CymaBay Therapeutics (CBAY), and Organon & Co. (OGN). These companies are all part of the "pharmaceutical preparations" industry.
Corcept Therapeutics (NASDAQ:CORT) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, community ranking, valuation and earnings.
Corcept Therapeutics has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Corcept Therapeutics had 1 more articles in the media than Perrigo. MarketBeat recorded 2 mentions for Corcept Therapeutics and 1 mentions for Perrigo. Corcept Therapeutics' average media sentiment score of 1.00 beat Perrigo's score of 0.88 indicating that Perrigo is being referred to more favorably in the news media.
Perrigo received 241 more outperform votes than Corcept Therapeutics when rated by MarketBeat users. However, 70.38% of users gave Corcept Therapeutics an outperform vote while only 66.70% of users gave Perrigo an outperform vote.
Corcept Therapeutics has a net margin of 21.86% compared to Corcept Therapeutics' net margin of -0.27%. Perrigo's return on equity of 21.98% beat Corcept Therapeutics' return on equity.
Corcept Therapeutics has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500.
Corcept Therapeutics currently has a consensus price target of $33.79, suggesting a potential upside of 34.12%. Perrigo has a consensus price target of $39.00, suggesting a potential upside of 21.16%. Given Perrigo's higher probable upside, equities research analysts plainly believe Corcept Therapeutics is more favorable than Perrigo.
93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 19.8% of Corcept Therapeutics shares are held by company insiders. Comparatively, 0.7% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Summary
Corcept Therapeutics beats Perrigo on 12 of the 18 factors compared between the two stocks.
Get Perrigo News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRGO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PRGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Related Companies and Tools